Pages that link to "Q71805034"
Jump to navigation
Jump to search
The following pages link to A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines (Q71805034):
Displaying 50 items.
- The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics (Q24291855) (← links)
- New targets for therapy in breast cancer: farnesyltransferase inhibitors (Q24796277) (← links)
- Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins (Q27027458) (← links)
- Targeting the RAS oncogene (Q27687198) (← links)
- Substrate specificity determinants in the farnesyltransferase β-subunit (Q27930129) (← links)
- A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics (Q28382899) (← links)
- Ras oncogenes: split personalities (Q29615405) (← links)
- Ras history: The saga continues (Q30404024) (← links)
- A novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochores (Q30635394) (← links)
- Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. (Q31115129) (← links)
- In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620. (Q33186288) (← links)
- Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours (Q33369069) (← links)
- Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study (Q33371141) (← links)
- Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities (Q33514156) (← links)
- Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells (Q33583266) (← links)
- Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors (Q33669995) (← links)
- Targeting protein prenylation for cancer therapy (Q33679239) (← links)
- Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer (Q33779007) (← links)
- Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway (Q33832634) (← links)
- TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development (Q33834762) (← links)
- Targeted therapies for pancreatic cancer (Q33899923) (← links)
- A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis (Q33995709) (← links)
- Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer (Q34013850) (← links)
- Combinatorial modulation of protein prenylation (Q34071002) (← links)
- Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy (Q34273680) (← links)
- Farnesyltransferase inhibitors: potential role in the treatment of cancer (Q34277794) (← links)
- Promotion of tumor development in prostate cancer by progerin (Q34413791) (← links)
- Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program (Q34637234) (← links)
- Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic (Q34817365) (← links)
- Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. (Q35012724) (← links)
- Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. (Q35044902) (← links)
- Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies (Q35091519) (← links)
- The Medical Management of Pancreatic Cancer: A Review (Q35108011) (← links)
- A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras (Q35193411) (← links)
- Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. (Q35525553) (← links)
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas (Q35525569) (← links)
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia (Q35628954) (← links)
- Farnesyltransferase inhibitors reverse taxane resistance (Q35774556) (← links)
- The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase (Q35774565) (← links)
- Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones (Q35858587) (← links)
- 8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells. (Q35878817) (← links)
- Inhibition of Ras for Cancer Treatment: The Search Continues (Q35944601) (← links)
- Unraveling the mechanism of the farnesyltransferase enzyme (Q35990341) (← links)
- Photochemical modulation of Ras-mediated signal transduction using caged farnesyltransferase inhibitors: activation by one- and two-photon excitation (Q36215605) (← links)
- Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death (Q36586495) (← links)
- Outlier kinase expression by RNA sequencing as targets for precision therapy. (Q36684371) (← links)
- Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas (Q36693797) (← links)
- Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition (Q36701461) (← links)
- Geranylgeranyltransferase I as a target for anti-cancer drugs (Q36809797) (← links)
- Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma (Q36926772) (← links)